In yesterday’s Wall Street session, Ocular Therapeutix Inc. (NASDAQ:OCUL) shares traded at $2.81, up 0.36% from the previous session.
As of this writing, 7 analysts cover Ocular Therapeutix Inc. (NASDAQ:OCUL). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $25.00 and a low of $5.00, we find $14.00. Given the previous closing price of $2.80, this indicates a potential upside of 400.0 percent. OCUL stock price is now -9.68% away from the 50-day moving average and -31.82% away from the 200-day moving average. The market capitalization of the company currently stands at $215.61M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 1 analysts who have given it a hold rating, whereas 6 have given it a buy rating. Brokers who have rated the stock have averaged $13.29 as their price target over the next twelve months.
On August 10, 2021, H.C. Wainwright Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $17, while ‘Berenberg’ rates the stock as ‘Buy’.
In other news, SUMMER ROAD LLC, 10% Owner bought 7,328 shares of the company’s stock on Nov 07. The stock was bought for $25,648 at an average price of $3.50. Upon completion of the transaction, the 10% Owner now directly owns 6,122,089 shares in the company, valued at $17.2 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 11, 10% Owner SUMMER ROAD LLC bought 10,000 shares of the business’s stock. A total of $38,993 was incurred on buying the stock at an average price of $3.90. This leaves the insider owning 6,114,761 shares of the company worth $17.18 million. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OCUL stock. A new stake in Ocular Therapeutix Inc. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $1,494,000. IKARIAN CAPITAL, LLC invested $745,000 in shares of OCUL during the first quarter. In the first quarter, TWO SIGMA INVESTMENTS, LP acquired a new stake in Ocular Therapeutix Inc. valued at approximately $556,000. GRAHAM CAPITAL MANAGEMENT, L.P. acquired a new stake in OCUL for approximately $534,000. ERGOTELES LLC purchased a new stake in OCUL valued at around $335,000 in the second quarter. In total, there are 174 active investors with 56.60% ownership of the company’s stock.
Friday morning saw Ocular Therapeutix Inc. (NASDAQ: OCUL) opened at $2.6600. During the past 12 months, Ocular Therapeutix Inc. has had a low of $2.57 and a high of $7.38. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.00, and a quick ratio of 4.90. The fifty day moving average price for OCUL is $3.0900 and a two-hundred day moving average price translates $4.1097 for the stock.
The latest earnings results from Ocular Therapeutix Inc. (NASDAQ: OCUL) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.25, missing analysts’ expectations of -$0.23 by -0.02. This compares to $0.03 EPS in the same period last year. The company reported revenue of $11.96 million for the quarter, compared to $12.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.55 percent. For the current quarter, analysts expect OCUL to generate $14.27M in revenue.
Ocular Therapeutix Inc.(OCUL) Company Profile
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
